US 11,958,865 B1
Leucine-rich repeat kinase 2 (LRRK2) inhibitors
Thomas Jensen, Valby (DK); Thomas Andersen, Valby (DK); Mikkel Jessing, Valby (DK); Jacob Nielsen, Valby (DK); Henrik Daver, Valby (DK); and Christopher Richard Jones, Valby (DK)
Assigned to H. Lundbeck A/S, Valby (DK)
Filed by H. Lundbeck A/S, Valby (DK)
Filed on Sep. 14, 2023, as Appl. No. 18/467,162.
Claims priority of application No. 22195861.4 (DK), filed on Sep. 15, 2022; and application No. 23168862.3 (DK), filed on Apr. 20, 2023.
Int. Cl. C07D 498/22 (2006.01)
CPC C07D 498/22 (2013.01) [C07B 2200/05 (2013.01)] 19 Claims
 
1. A compound of formula IIa, or a pharmaceutically acceptable salt thereof, wherein:

OG Complex Work Unit Chemistry
X is CH, CR1 or N;
Y is CH, CR1 or N;
R1 is independently selected from the group consisting of a C1-C3 alkyl, a C1-C3 haloalkyl, and a halogen;
R2 is selected from a C1-C3 alkyl and an isotopically labelled C1-C3 alkyl;
R3 is selected from the group consisting of a halogen, a cyano, and a C1-C3 haloalkyl;
R4 is selected from the group consisting of a C1-C3 alkyl, an isotopically labelled C1-C3 alkyl, a C1-C3 haloalkyl, a O—C1-C3 alkyl, an isotopically labelled O—C1-C3 alkyl, a O—C1-C3 haloalkyl, and a O—C3-C6 cycloalkyl;
n is 0, 1 or 2.